605 completed. 605 Phase 1, 175 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 605 | Completed 605 |
| Phase 2 | 175 | Completed 175 |
Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer [68Ga]Ga-OncoACP3 - Prostate Cancer | Phase 1 | Completed | Philogen S.p.A. | 20 | 2026-05-27 | 2026-10-27 |
| A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 CKD-846, D091 - Benign Prostate Hypertrophy(BPH) | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 34 | 2026-02-23 | 2026-07-21 |
| A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers AD-116, AD-1161 - Benign Prostatic Hyperplasia | Phase 1 | Completed | Addpharma Inc. | 44 | 2026-01-22 | 2026-07-28 |
| BOTOX Injection Technique for LUTS Due to BPH Botulinum Toxin Type A (BoNT-A) - Benign Prostatic Hyperplasia | Phase 1 | Completed | Benha University | 60 | 2025-10-01 | 2026-06-12 |
| A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects HRS-5041 Tablets, Rifampicin Capsule - Prostate Cancer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 16 | 2025-06-20 | 2025-09-10 |
| A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults Flotufolastat F-18 Injection - Prostate Cancer | Phase 1 | Completed | Sinotau Pharmaceutical Group | 6 | 2025-06-07 | 2026-11-10 |
| A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer [68Ga]Ga-OncoACP3 - Prostate Cancer, Prostate Cancer Metastatic Disease | Phase 1 | Completed | Philogen S.p.A. | 20 | 2025-04-08 | 2026-01-06 |
| Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio), Lidocaine, Biopsy of Prostate - Prostate Cancer | Phase 1 / Phase 2 | Completed | University of Washington | 350 | 2025-01-09 | 2026-02-17 |
| Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen One single intravenous injection of [177Lu]Lu-BQ7876 - Prostate Cancers | Phase 1 | Completed | Tomsk National Research Medical Center of the Russian Academy of Sciences | 7 | 2024-10-01 | 2026-06-26 |
| Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants HRS-5041 dose level 1, HRS-5041 dose level 2 - Prostate Cancer | Phase 1 | Completed | Atridia Pty Ltd. | 24 | 2024-09-25 | 2025-03-18 |
| A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) [¹⁴C]Opevesostat, Prednisone, Fludrocortisone - Metastatic Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 8 | 2024-09-19 | 2024-10-23 |
| A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011) MK-5684, Prednisone, Fludrocortisone acetate - Prostatic Neoplasms | Phase 1 | Completed | Merck Sharp & Dohme LLC | 12 | 2024-07-11 | 2024-10-15 |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors APL-5125 - Colorectal Cancer, Cholangiocarcinoma | Phase 1 | Completed | Apollo Therapeutics Ltd | 27 | 2024-06-18 | 2026-10-05 |
| Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients 68Ga-NYM032 injection - Prostate Cancer | Phase 1 / Phase 2 | Completed | Norroy Bioscience Co., LTD | 20 | 2024-06-04 | 2025-05-21 |
| Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy NeuroSAFE procedure, LaserSAFE procedure - Prostate Cancer | Phase 1 / Phase 2 | Completed | University College, London | 21 | 2024-05-15 | 2025-01-10 |
| A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) Opevesostat, Dexamethasone, Fludrocortisone - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2024-01-30 | 2026-03-19 |
| A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) Opevesostat, Dexamethasone, Fludrocortisone acetate - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 7 | 2023-11-14 | 2026-04-27 |
| A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 CKD-846, D091 - Benign Prostate Hypertrophy(BPH) | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2023-11-13 | 2026-01-14 |
| Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413 Whole body study and SPECT with [99mTc]Tc-BQ0413 - Prostate Cancer | Phase 1 | Completed | Tomsk National Research Medical Center of the Russian Academy of Sciences | 10 | 2023-10-19 | 2026-06-24 |
| A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. Saruparib (AZD5305), Darolutamide, No Treatment - Prostate Cancer | Phase 1 | Completed | AstraZeneca | 113 | 2023-09-21 | 2026-06-30 |
Showing 20 of 605. Sign in to see all of them.
Prostatic Neoplasms (552) · Breast Neoplasms (91) · Neoplasms (70) · Carcinoma, Non-Small-Cell Lung (53) · Ovarian Neoplasms (53) · Prostatic Hyperplasia (48) · Pancreatic Neoplasms (46) · Urinary Bladder Neoplasms (45) · Colorectal Neoplasms (40) · Lung Neoplasms (39) · Melanoma (35) · Colonic Neoplasms (34) · Neoplasm Metastasis (33) · Esophageal Neoplasms (32) · Head and Neck Neoplasms (31)
Urogenital Diseases (605) · Genital Diseases (604) · Male Urogenital Diseases (604) · Genital Diseases, Male (601) · Neoplasms by Site (554) · Genital Neoplasms, Male (553) · Urogenital Neoplasms (551) · Neoplasms (487) · Female Urogenital Diseases (106) · Female Urogenital Diseases and Pregnancy Complications (106) · Skin and Connective Tissue Diseases (106) · Skin Diseases (105) · Breast Diseases (97) · Neoplasms by Histologic Type (91)
Docetaxel (42) · Prednisone (27) · enzalutamide (21) · Abiraterone Acetate (18) · Radiotherapy (16) · Tamsulosin (14) · bicalutamide (13) · Dutasteride (12) · Goserelin (12) · Leuprolide (10) · Estramustine (8) · Paclitaxel (8) · abiraterone (8) · pembrolizumab (8) · Radiotherapy, Intensity-Modulated (7)
National Cancer Institute (NCI) (41) · Memorial Sloan Kettering Cancer Center (32) · GlaxoSmithKline (14) · M.D. Anderson Cancer Center (12) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (11) · AstraZeneca (10) · Janssen Research & Development, LLC (10) · Weill Medical College of Cornell University (9) · University Health Network, Toronto (8) · Bayer (7) · Millennium Pharmaceuticals, Inc. (7) · Pfizer (7) · Chong Kun Dang Pharmaceutical (6) · Merck Sharp & Dohme LLC (6) · Molecular Insight Pharmaceuticals, Inc. (6)
United States (417) · Canada (44) · United Kingdom (38) · South Korea (25) · Australia (17) · Spain (15) · Netherlands (14) · France (13) · China (12) · Germany (12) · Belgium (11) · Denmark (11) · Japan (10) · Italy (9) · Russia (7)
Michael Morris, MD (6) · Susan Slovin, MD, PhD (6) · James L Gulley, M.D. (5) · Scott Tagawa, MD (4) · Howard I. Scher, MD (3) · Keith A. Rodvold (3)
PMID 33465252, PMID 36383907, PMID 19949018, PMID 22002018, PMID 22747660, PMID 25475068, PMID 28800206, PMID 37496366, PMID 41044356, PMID 10661346, PMID 11828001, PMID 12694838, PMID 14504052, PMID 14529764, PMID 14967428, PMID 15590164, PMID 15671557, PMID 15735119, PMID 15936549, PMID 16145049, PMID 16597660, PMID 17707059, PMID 17920349, PMID 18245546, PMID 18384719, PMID 18464023, PMID 18523152, PMID 19192962, PMID 19349545, PMID 19375217, PMID 19499186, PMID 19577865, PMID 19706807, PMID 20068553, PMID 20179219, PMID 20346578, PMID 20398037, PMID 20398925, PMID 20407240, PMID 20501622, PMID 20598811, PMID 20818327, PMID 20824184, PMID 21106711, PMID 21163871, PMID 21377288, PMID 21414514, PMID 21917625, PMID 21976132, PMID 22044694
P30CA008748 (6), 2014 (5), P30CA072720 (4), 2015 (3), 2017 (3), P30CA015083 (3), P30CA016672 (3), P50CA058204 (3), U01CA069856 (3), U01CA069912 (3), P30CA016056 (2), P30CA093373 (2), P30CA124435 (2), R01CA207645 (2), U01CA062505 (2)